BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Study or Subgroup	Sacubitril/valsartan Events	Sacubitril/valsartan Total	Control Events	Control Total	Weight	Risk Ratio M-H, Fixed, 95% CI
17.2.1 HFrEF						
AWAKE-HF 2019	5	69	4	70	0.2%	1.27 [0.36, 4.52]
CLCZ696B2223	0	8	0	8		Not estimable
EVALUTE-HF 2019	1	231	1	232	0.0%	1.00 [0.06, 15.96]
Li J 2019 (1)	3	62	5	64	0.2%	0.62 [0.15, 2.48]
OUTSTEP-HF	19	309	28	310	1.2%	0.68 [0.39, 1.19]
PARADIGM-HF 2014	1937	4203	2142	4229	94.6%	0.91 [0.87, 0.95]
PIONEER-HF 2018	41	440	74	441	3.3%	0.56 [0.39, 0.79]
PRIME-HF 2019	7	60	9	58	0.4%	0.75 [0.30, 1.89]
Subtotal (95% CI)		**5382**		**5412**	**100.0%**	**0.89 [0.86, 0.94]**
Total events	2013		2263			
Heterogeneity: Chi² = 8.99, df = 6 (P = 0.17); I² = 33%						
Test for overall effect: Z = 4.96 (P < 0.00001)						
17.2.2 HFpEF						
Huang SB 2019	2	39	9	38	0.6%	0.22 [0.05, 0.94]
PARAGON-HF 2019	1424	2419	1416	2402	97.3%	1.00 [0.95, 1.05]
PARAMOUNT 2012	22	149	30	152	2.0%	0.75 [0.45, 1.24]
Subtotal (95% CI)		**2607**		**2592**	**100.0%**	**0.99 [0.94, 1.04]**
Total events	1448		1455			
Heterogeneity: Chi² = 5.49, df = 2 (P = 0.06); I² = 64%						
Test for overall effect: Z = 0.48 (P = 0.63)						



Test for subgroup differences: Chi² = 9.18, df = 1 (P = 0.002), I² = 89.1%